Abstract: The present invention relates to a pyrazole compound and a preparation method therefor and a use thereof. In particular, the present invention relates to a compound shown in Formula I, a pharmaceutical composition containing same or a pharmaceutically acceptable form thereof, a pharmaceutical composition thereof, a preparation method therefor, and a use thereof.

Abstract: The present invention provides an anti-ErbB2 antibody-drug conjugate, a composition comprising the conjugate, a method for preparing the conjugate, and use of the conjugate.

Abstract: Provided are a salt and a crystal form of a pyrimidine compound, and preparation methods therefor. Specifically, provided are a salt and a crystal form of a compound I, including a crystal form of the salt, and preparation methods therefor.

Abstract: Provided is an anti-PD-L1 antibody preparation, including an anti-PD-L1 antibody, a buffer solution and sodium chloride, without added sugars and/or sugar alcohols. Also provided is the use of the anti-PD-L1 antibody preparation in the preparation of drugs for preventing and/or treating and/or adjuvant treating and/or diagnosing a tumor or anemia.

Abstract: The invention provides methods for treating a source oil phase consisting of heavy oil, bitumen, a mixture of heavy oil and bitumen, a mixture of solvent and heavy oil or bitumen or both. The method comprises: introducing the source oil phase to a lower reservoir section of a device, flowing the source oil phase through an array of vertically extending heated pipes with an inert gas so as to thermally separate a vaporized light oil phase component from a heated liquid source oil phase, and segregating fluid flows by density in an upper fluid separating manifold to provide a light product fluid and a heavy product fluid.

Abstract: A geothermal reservoir induces gasification and water gas shift reactions to generate hydrogen. The hydrogen or protons are produced to surface by using hydrogen-only or proton-only membranes in production wells. Energy from the reservoir is produced to surface as protons or hydrogen.

Abstract: Dynamic snapshot scheduling techniques are provided using storage system metrics. One method comprises obtaining a schedule for generating snapshots of a portion of a storage system; automatically adjusting snapshot generation parameters in the schedule based on: (i) a current storage pool usage metric, (ii) an input/output metric of at least one storage resource in the portion of the storage system, (iii) a measure of snapshots in a destroying state, and/or (iv) a measure of a number of created snapshots; and initiating a generation of a snapshot of the storage system portion in accordance with the adjusted schedule. A snapshot generation frequency may be increased in response to an increase of: the current storage pool usage metric, the number of snapshots in the destroying state, and/or the number of created snapshots. A snapshot generation frequency may be decreased in response to an increase of the I/O metric of the at least one storage resource.

Abstract: The present invention belongs to the field of pharmaceutical chemistry, and relates to a substituted pyrazine compound, a pharmaceutical composition comprising same, and the use thereof. In particular, the present invention relates to a compound with the structure of formula (I), which exhibits a good SHP2 inhibiting activity, and can act as an efficient SHP2 inhibitor for preventing and/or treating SHP2-related diseases.

Abstract: Provided are a chimeric antigen receptor (CAR) or CAR construct containing antibodies against BCMA and CD19, a nucleic acid molecule encoding the CAR or CAR construct, a modified immune cell, and a method for preparing the immune cell. The CAR or CAR construct and the modified immune cell are used for the prevention and/or treatment of B cell related conditions (e.g., B cell and plasma cell related malignant tumors or autoimmune diseases (such as systemic lupus erythematosus)), and can effectively avoid target escape and prevent the recurrence of multiple myeloma.

Abstract: The present application relates to the field of treatment of diseases, and in particular, to an anti-CLDN18.2 antibody or an antigen-binding fragment thereof, nucleic acid molecules for encoding said antibody and fragment, and method for preparing said antibody and fragment. The anti-CLDN18.2 antibody or the antigen-binding fragment thereof has high specificity and affinity to CLDN18.2, and can effectively bind to CLDN18.2 and mediate the killing of CLDN18.2 expressing cells. Therefore, the present application further relates to a pharmaceutical composition comprising the antibody or the antigen-binding fragment thereof, and use thereof in the preparation of drugs, wherein the drugs are used for the prevention and/or treatment of tumors.

Abstract: The present invention generally relates to an isoxazole derivative, a preparation therefor, and a use thereof. In particular, the present invention provides a farnesoid X receptor (FXR) agonist compound, and a stereoisomer, a tautomer, a polymorph, a solvate (e.g., a hydrate), a pharmaceutically acceptable salt, an ester, a metabolite, and an N-oxide, and the chemically protected forms and prodrugs thereof. The present invention further provides a preparation method for the compound, an intermediate thereof, and a pharmaceutical composition and kit containing the same and used thereof for treating FXR-mediated diseases or conditions.

Abstract: The present invention relates to the field of treatment of diseases and immunology. Specifically, the present invention relates to an anti-LAG-3 antibody or an antigen-binding fragment thereof, nucleic acid molecules for encoding said antibody and fragment, and method for preparing said antibody and fragment. The anti-LAG-3 antibody or the antigen-binding fragment thereof according to the present invention has high specificity and high affinity to LAG-3, can effectively block the binding of LAG-3 to MHC II and/or FGL1, and can inhibit and/or block intracellular signaling mediated by LAG-3 binding to MHC II and/or FGL1. Therefore, the present invention further relates to a pharmaceutical composition comprising the antibody or the antigen-binding fragment thereof, and use of the pharmaceutical composition in the preparation of drugs.

Abstract: Provided are tetrahydroisoquinoline derivatives, the preparation and use thereof. More specifically, provided are the tetrahydroisoquinoline derivatives or a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, polymorph, solvate, isotopically labeled compound, metabolite or prodrug thereof. Further provided are a preparation process of the compound, the intermediates, a pharmaceutical composition comprising the compound and the use thereof in the treatment or prevention of a thromboembolic disorder.

Abstract: A hydrocarbon reservoir is treated with heat to induce gasification, water-gas shift, and/or aquathermolysis reactions to generate gases including hydrogen. The hydrogen alone is produced to the surface by using hydrogen-only membranes in the production wells.

Abstract: Related are an anti-TSLP antibody or an antigen-binding fragment thereof, nucleic acid molecules coding the same, and a method for preparing the same. The anti-TSLP antibody or the antigen-binding fragment thereof have high affinity to TSLP, capable of effectively binding with TSLP and blocking the proliferative effect of TSLP with respect to Ba/F3-hTSLPR-hIL7R? cells, and blocking the capability of TSLP in activating and secreting cytokines with respect to PBMC. At the same time, further related are a medicinal composition comprising the antibody or the antigen-binding fragment thereof, and uses of the composition in preparing a medicament for preventing and/or treating asthma, allergic inflammation, an allergic reaction or autoimmune disease.

Abstract: The invention provides methods for treating a source oil phase consisting of heavy oil, bitumen, a mixture of heavy oil and bitumen, a mixture of solvent and heavy oil or bitumen or both. The method comprises: introducing the source oil phase to a heated lower section of a device to provide an interior source oil phase; heating the interior source oil phase so as to thermally separate a light oil phase component therefrom and provide a vaporized light oil; and condensing the vaporized light oil phase on one or more internal cooling fins housed within the upper section of the device, to provide a condensed light oil phase liquid, wherein the internal cooling fins are angled so as to direct the condensed light oil phase liquid downwardly to a light end collection system.

Abstract: The invention provides methods for treating a source oil phase consisting of heavy oil, bitumen, a mixture of heavy oil and bitumen, a mixture of solvent and heavy oil or bitumen or both. The method comprises: introducing the source oil phase to a lower reservoir section of a device, flowing the source oil phase through an array of vertically extending heated pipes with an inert gas so as to thermally separate a vaporized light oil phase component from a heated liquid source oil phase, and segregating fluid flows by density in an upper fluid separating manifold to provide a light product fluid and a heavy product fluid.

Abstract: Disclosed are a solid form of (E)-3-((R)-4-(((R)-6-(2-chloro-4-fluorophenyl)-5-(methoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydropyrimidin-4-yl)methyl)morpholin-2-yl)acrylic acid, a preparation method therefor, a pharmaceutical composition comprising same, and the use thereof in the preparation of drugs for preventing or treating viral diseases.

Abstract: Provided are a recombinant bispecific antibody against CTLA-4 and PDL-1, a nucleic acid molecule for encoding the antibody, a vector and a host cell comprising the nucleic acid molecule, and a method for preparing the antibody. Also provided are a pharmaceutical composition comprising the bispecific antibody, and usage of the bispecific antibody in preparation of the pharmaceutical composition.

Abstract: The present invention relates to a docetaxel albumin nanoparticle pharmaceutical composition, a preparation method therefor, and a use thereof for manufacturing drugs for treating cancer. The pharmaceutical composition comprises docetaxel, albumin and amino acid(s), wherein the weight ratio between albumin and docetaxel is no more than 50, preferably is 20:1 to 1:1, and the weight ratio between amino acid(s) and docetaxel is not less than 0.5, preferably is 1:1 to 20:1.